Heather C Beckwith

Heather C Beckwith is an Associate Professor in the Department of Medicine - Hematology, Oncology, Transplant at the University of Minnesota, School of Medicine. She is actively involved in clinical and translational research focused on breast cancer, particularly in neoadjuvant therapy, targeted treatments, and cardio-oncology. Her work is supported by multiple grants from major pharmaceutical sponsors, and she serves as Principal Investigator on several national clinical trials.

Her research interests include:

• Breast cancer therapeutics and biomarkers
• Neoadjuvant and endocrine therapy
• HER2-positive and HR+ advanced breast cancer
• Cardiovascular effects of cancer treatments
• Patient outcomes and risk stratification

Recent publications highlight her role in the I-SPY2 and I-SPY SURMOUNT trials, evaluating novel agents such as datopotamab-deruxtecan and ARX788. The research trends show a strong emphasis on adaptive trial design, combination therapies, and personalized treatment approaches in early and advanced breast cancer.

Scientific contributions include:

• Phase II and III clinical trials in breast cancer
• Studies on biomarkers and treatment response
• Investigations into cardiovascular toxicity in survivors

Dr. Beckwith leads multiple externally funded research projects and collaborates with national consortia. She has contributed to datasets such as the 'COVID-19 Concerns among Physicians who treat cancer' survey, reflecting broader engagement in oncology policy and practice. She is also affiliated with multi-center teams focused on improving outcomes in high-risk and metastatic disease settings.